Magnetic resonance spectroscopic imaging and volumetric measurements of the brain in patients with postcancer fatigue: a randomized controlled trial. — ME/CFS Atlas
E1 ReplicatedModerate confidencePEM not requiredRCTPeer-reviewedReviewed
Standard · 3 min
Magnetic resonance spectroscopic imaging and volumetric measurements of the brain in patients with postcancer fatigue: a randomized controlled trial.
Prinsen, Hetty, Heerschap, Arend, Bleijenberg, Gijs et al. · PloS one · 2013 · DOI
Quick Summary
This study looked at whether brain structure and chemistry differences seen in chronic fatigue syndrome patients also appear in cancer survivors with fatigue. Researchers compared fatigued and non-fatigued cancer survivors using brain imaging and measured whether cognitive behavior therapy changed these brain markers. They found no significant differences in brain structure or chemistry between fatigued and non-fatigued groups, and treatment did not change these markers even though fatigue improved.
Why It Matters
This study challenges assumptions that postcancer fatigue and ME/CFS share identical neurobiological mechanisms. Understanding whether fatigue syndromes of different etiologies have different underlying brain pathology is crucial for developing targeted treatments and helps clarify whether ME/CFS-focused neuroimaging findings are specific to that condition or general markers of fatigue.
Observed Findings
No significant differences in global brain volumes, subcortical volumes, metabolite concentrations, or metabolite ratios between fatigued and non-fatigued cancer survivors at baseline.
Change scores in volumetric and metabolic parameters from baseline to 6-month follow-up did not differ significantly between cognitive behavior therapy and waitlist control groups.
Patients receiving cognitive behavior therapy reported significantly greater decreases in fatigue severity compared to waitlist controls.
Brain imaging markers remained stable over 6 months regardless of fatigue symptom improvement with treatment.
Inferred Conclusions
Postcancer fatigue may not share the same brain volumetric and metabolic abnormalities previously identified in chronic fatigue syndrome.
The neurophysiological basis of postcancer fatigue may differ fundamentally from chronic fatigue syndrome despite their clinical similarity.
Fatigue improvement through cognitive behavior therapy occurs independently of changes in brain structure and metabolite levels measurable by MR spectroscopy.
Remaining Questions
What neurobiological mechanisms do underlie postcancer fatigue if not brain volume and metabolite abnormalities?
Are ME/CFS-associated brain abnormalities truly disease-specific, or do alternative imaging modalities reveal similar findings in postcancer fatigue?
What This Study Does Not Prove
This study does not prove that brain structure and metabolism play no role in postcancer fatigue—only that they were not detectable by these specific imaging methods in this sample. It does not establish whether ME/CFS and postcancer fatigue are fundamentally different conditions, as the negative findings could reflect methodological limitations rather than biological truth. The findings cannot determine whether other neurobiological markers (e.g., neuroinflammation, mitochondrial function) distinguish these conditions.
Tags
Symptom:Fatigue
Biomarker:MetabolomicsNeuroimaging
Method Flag:PEM Not DefinedWeak Case DefinitionSmall Sample
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.